Delays in diagnosing and treating psoriatic arthritis – a common inflammatory disorder affecting 112 in every 100,000 adults – are causing irreparable ...

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Dr. Reddy’s Laboratories RDY and China-based Bio-Thera Solutions announced that they have entered into commercialization and license agreements for BAT2206, a proposed biosimilar of Johnson & ...

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It's used to treat several types of ...

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

Korea: A recent retrospective cohort study published in the Journal of the American Academy of Dermatology explored the link ...

Medically reviewed by Anita C. Chandrasekaran, MD Many people associate psoriatic arthritis (PsA) with itchy, scaly skin and ...

Affiliate content. Discover the best products for arthritis in hands, including supplements, creams, and tools designed to ...

STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...